NCT00694200 - Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Breast Cancer

Interventions

DRUG

Vinorelbine

Vinorelbine per os 50 mg 3 times a week

DRUG

Bevacizumab

Bevacizumab 10 mg/kg IV every 14 days

Trial Locations (9)

University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupoli

"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens

"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens

"Marika Iliadis Hospital of Athens, Dep of Medical Oncology", Athens

401 Military Hospital of Athens, Athens

Air Forces Military Hospital of Athens, Athens

University Hospital of Crete, Dep of Medical Oncology, Heraklion

State General Hospital of Larissa, Dep of Medical Oncology, Larissa

"Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki